CLIA - CME Course for Lab Directors of Moderate Complexity Laboratories

Monday, July 1, 2024, 12:00 AM - Wednesday, June 30, 2027, 11:59 PM

This course was originally released 12/1/1995. The latest review and update was completed 6/30/2024.

CLIA -  CME Course for Lab Directors of Moderate Complexity Laboratories is designed to meet the Clinical Laboratory Improvement Amendments (CLIA) requirement at 42 CFR 493.1405(b)(2)(ii)(B). (This requirement is specific to physician and podiatrist directors of moderate complexity laboratories.)  

Intended Audience
Doctors of medicine, osteopathy and podiatry seeking to fulfill the CLIA requirement at 42 CFR 493.1405(b)(2)(ii)(B). 

How to Complete the Course
There are 20 interactive self-paced modules that must be completed in order. Each module includes a post-test for which a score of 70% or higher is required, and the expectation is that the learner will pass the post-test within 3 attempts. The course will take approximately 20 hours to complete.  Click the Course Content & Tests tab above for step-by-step instructions and to access the course materials. 

AMA PRA Category 1 Credits™ (20.00 hours), Non-Physician Attendance (20.00 hours)

Registration fee:  $475.00. The course must be completed within 12 months of registering.

MOC is not available with this course.

In support of improving patient care, the University of Iowa Roy J. and Lucille A. Carver College of Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

 

Credit Designation
Physicians: The University of Iowa Roy J. and Lucille A. Carver College of Medicine designates this enduring material for a maximum of 20.0 AMA PRA Category 1 Credit(s)^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Other Participants: A certificate of participation will be available after successful completion of the course. (It is the responsibility of licensees to determine if this continuing education activity meets the requirements of their professional licensure board.)

Matthew D. Krasowski, MD, PhD
Clinical Professor of Pathology
Medical Director, Clinical Chemistry and Point of Service Laboratories
Medical Director, Iowa River Landing Laboratory
Vice Chair for Clinical Pathology and Laboratory Services
University of Iowa Carver College of Medicine
University of Iowa Health Care

Cassie Hartgrave, MPH, MLS(ASCP)cm
Manager, Quality Assurance and Compliance, Department of Pathology
University of Iowa Health Care

 

Mitigation of Relevant Financial Relationships

University of Iowa Roy J. and Lucille A. Carver College of Medicine adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests). 

Financial Disclosures

• Matthew D. Krasowski, MD, PhD, has disclosed the following relationships:  Roche Molecular Systems, Inc. - sponsored research; Truvian Sciences - advisory.
• All other faculty, planners, and reviewers disclosed no relevant financial relationships.

Relevant financial relationships were mitigated prior to the publication of the activity.